

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 01948/074002		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 C.F.R. §1.98(b))		Serial No. 09/885,768		
				Applicant Mark A. Exley et al.		
				Filing Date June 19, 2001		
				Group 1645		
				Customer No. 21559		
IDS Filed October 30, 2002						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
<i>E</i>	EP 0 677 533 A	18 Oct. 1995	EPO			No
<i>E</i>	EP 1 025 854 A	9 August 2000	EPO			Yes (abstract)
<i>✓</i>	WO 99/34209	8 July 1999	WIPO			No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
<i>E</i>	Exley et al., "CD161 (NKR-P1A) Costimulation of CD1d-dependent Activation of Human T Cells Expressing Invariant Vα24JαQ T Cell Receptor α Chains," <i>J. Exp. Med.</i> 188(5):867-876 (1998).					
<i>E</i>	Nicol et al., "Human Invariant Vα24* Natural Killer T Cells Activated By α-galactosylceramide (KRN7000) Have Cytotoxic Anti-tumour Activity Through Mechanisms Distinct From T Cells And Natural Killer Cells," <i>Immunology</i> 99:229-234 (2000).					
	Wilson et al., "Development of Monoclonal Antibodies to Vα24JαQ T Cells Detects Alterations in Cell Frequency in New-Onset Type 1 Diabetes Patients," <i>Diabetes</i> vol. 50, Supplement 2 (2001).					
EXAMINER <i>E</i>			DATE CONSIDERED 3/4/06			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

Reference
missingRECEIVED
NOV 07 2002
TECH CENTER 1600/2900

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 01948/074002		
				Serial No. 09/885,768		
				Applicant Mark A. Exley et al.		
				Filing Date June 19, 2001		
				Group 1644		
				IDS Filed October 21, 2004		
				Customer No. 21559		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
<input checked="" type="checkbox"/>	Benlagha et al., "In Vivo Identification of Glycolipid Antigen-Specific T Cells Using Fluorescent CD1d Tetramers," J. Exp. Med. 191:1895-1903 (2000).					
<input checked="" type="checkbox"/>	Matsuda et al., "Tracking the Response of Natural Killer T Cells to a Glycolipid Antigen Using Cd1d Tetramers," J. Exp. Med. 192:741-753 (2000).					
<input checked="" type="checkbox"/>	Naidenko et al., "Binding and Antigen Presentation of Ceramide-Containing Glycolipids by Soluble Mouse and Human CD1d Molecules," J. Exp. Med. 190:1069-1079 (1999).					
EXAMINER <i>Sign</i>			DATE CONSIDERED 3/4/06			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						